LHDX - LHDX STOCK NEWS

Lucira Health has received an Authorization with Conditions from Health Canada for its LUCIRA™ CHECK IT COVID-19 test kit, becoming the first self-test approved for use by individuals with or without symptoms. This test kit delivers PCR-quality results in under 30 minutes and is priced at approximately $75 CAD. CEO Erik Engelson stated that the test enhances safety and health. The kit is also the only FDA-authorized over-the-counter PCR test in the U.S., further solidifying Lucira’s market presence.

Lucira Health announced the launch of its COVID-19 self-testing program for NBA fans, debuting on April 23 at the Chase Center in San Francisco as the Golden State Warriors host the Denver Nuggets. Ticket buyers can receive a free Lucira™ Check It test kit. With results in as little as 11 minutes, the test provides PCR-quality accuracy. Lucira's test, cleared for OTC sale by the FDA, can be used independently, enhancing safety at large events while meeting California's health guidelines.

Lucira Health, Inc. (LHDX) has launched an innovative COVID-19 self-testing program for NBA fans, debuting with the Golden State Warriors on April 23. Eligible ticket buyers can obtain a free Lucira™ Check It test kit, providing results in as little as 11 minutes. This test, authorized for over-the-counter sale by the FDA, offers PCR-quality accuracy and does not require a healthcare provider. Fans must show proof of vaccination or a negative COVID-19 test within 48 hours to enter the Chase Center. Lucira aims to enhance safety at large events while expanding access to its testing technology.

Lucira Health, Inc. (Nasdaq: LHDX) received FDA Emergency Use Authorization for its LUCIRA CHECK IT™ test kit for COVID-19, enabling over-the-counter sales. Priced at $55, the kit provides PCR-quality results in under 30 minutes, suitable for all users. With an accuracy of 98% compared to a leading molecular test, it was developed with feedback from over 1,000 people. Preliminary revenue for Q1 2021 is estimated between $4.0 million and $4.5 million. Despite market challenges, Lucira believes its product will benefit from the trend of at-home testing.

Lucira Health, Inc. (Nasdaq: LHDX) announced its Lucira molecular test kit can effectively detect the 'double mutant' COVID-19 variant, first identified in India and later in California. The company's test has demonstrated a 99.9% reactivity to available COVID-19 viral sequences. Designed for easy self-administration, results are available within 30 minutes. In clinical trials, Lucira achieved a 94% positive agreement with high sensitivity compared to leading molecular tests. The LUCIRA All-In-One Test Kit maintains accuracy and reliability, addressing the evolving challenges of COVID-19 detection.

Lucira Health, Inc. (Nasdaq: LHDX) has announced the availability of its COVID-19 All-In-One Test Kits for U.S. healthcare providers. These FDA-authorized kits can provide results in under 30 minutes and are designed for both in-office and at-home use. Each kit costs $50 and is manufactured in the U.S., featuring a simple process for self-administration. Clinical trials indicate accuracy comparable to leading molecular assays, with 94% agreement for positive results and 98% for negative ones. The kits are aimed at facilitating quicker COVID-19 testing amid ongoing concerns.

Lucira Health recently closed its upsized IPO, selling 10,350,000 shares at $17.00 per share, generating gross proceeds of $175.95 million. The underwriters exercised their option for an additional 1,350,000 shares. Lucira's common stock commenced trading on Nasdaq under the symbol 'LHDX' on February 5, 2021. The offering was managed by BofA Securities and William Blair, with registration statements effective as of February 4, 2021. Lucira Health specializes in innovative infectious disease testing kits that deliver accurate results in a consumer-friendly format.

Lucira Health announced the pricing of its upsized initial public offering (IPO) of 9,000,000 shares at $17.00 per share, aiming to raise approximately $153 million before expenses. The offering includes a 30-day option for underwriters to purchase an additional 1,350,000 shares. Trading on the Nasdaq under the ticker symbol LHDX is set to commence on February 5, 2021, with the closing expected on February 9, 2021, subject to customary conditions. This IPO is pivotal as Lucira develops innovative infectious disease test kits that deliver accurate results in user-friendly formats.